Form 4: Aura Biosciences CTO Sells Shares for Tax Obligations

Aura Biosciences' Chief Technology Officer, Mark Plavsic, sold 12,169 shares of common stock at $6.35 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mark Plavsic, Chief Technology Officer of Aura Biosciences, Inc. (AURA), reported a transaction on October 16, 2025.
• He disposed of 12,169 shares of common stock at a price of $6.35 per share.
• The sale was automatic and non-discretionary, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Plavsic beneficially owns 197,287 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations upon RSU vesting, which is a neutral event for insider sentiment.

Positives

• The sale was non-discretionary and solely for tax withholding purposes related to restricted stock unit vesting, not an indication of a change in investment sentiment.

Negatives

• Chief Technology Officer Mark Plavsic's direct beneficial ownership decreased by 12,169 shares.

Future Outlook

NA

Management Comments

• The sales represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor reduction in insider ownership, but the non-discretionary nature of the sale for tax purposes mitigates concerns about insider selling.
• Employees: Standard RSU vesting and tax handling practices are consistent with typical executive compensation structures.

Key Dates

Recommendation

The Form 4 details a routine, non-discretionary sale of shares by the Chief Technology Officer to cover tax withholding obligations related to restricted stock unit vesting. This type of transaction is a common and expected event for executive compensation and does not typically signal a change in the company's fundamentals or the insider's long-term view. Therefore, it does not provide new information that would alter a 'hold' recommendation.

Keywords

Aura Biosciences, AURA, Mark Plavsic, Chief Technology Officer, CTO, insider trading, Form 4, stock sale, RSU, restricted stock units, tax withholding